ĐIỀU TRỊ CHỬA NGOÀI TỬ CUNG CHƯA VỠ BẰNG METHOTREXATE ĐƠN LIỀU TẠI BỆNH VIỆN ĐA KHOA TỈNH VĨNH PHÚC

Abstract

Objective: To describe the clinical and subclinical characteristics of unruptured ectopic pregnancy patients treated with single-dose Methotrexate at Vinh Phuc Provincial General Hospital from 2022 to 2024, and to evaluate the treatment outcomes of these patients. Subjects and Methods: A retrospective study was conducted on 98 patients diagnosed with ectopic pregnancy and treated with single-dose Methotrexate from May 1, 2022, to April 30, 2024; selective criteria:  initial β-hCG levels ≤ 5000 IU/l and an ectopic pregnancy mass  ≤ 3,5 cm on ultrasound, hemodynamic stability, no fetal cardiac activity. Results: The accumulative  success rate of treatment: one dose: 67,3%;  double dose: 87,8%, triple dose  92.9%. Patients with initial β-hCG levels < 1000 IU/l had a success rate of 97.1%, 1000 - < 2000 UI/l: 87.5%; 2000 – 5000 UI/l: 78,6%. For a ectopic pregnancy mass size on ultrasound: < 1.5 cm the success rate was 98.2%; 1,5 - < 3 cm: 89.5%. The absence of cul-de-sac fluid on ultrasound was associated with a success rate: 98.0% ; ≤ 15 mm: 91.2%; >15 mm: 80.0%. Conclusion: Single-dose Methotrexate is a relatively effective treatment for ectopic pregnancy, a success rate related with initial selective factors as β-hCG levels, ectopic pregnancy mass sizes on ultrasound, and intraabdominal  fluid.